Y Ohe

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. ncbi request reprint A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 15:45-50. 2004
  2. ncbi request reprint Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients
    Y Ohe
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 31:100-6. 2001
  3. doi request reprint Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Clin Cancer Res 14:4206-12. 2008
  4. ncbi request reprint Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Panminerva Med 44:205-12. 2002
  5. ncbi request reprint Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, National Cancer Center Research Institute, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 94:729-34. 2003
  6. ncbi request reprint Chemoradiotherapy for lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo 104 0045, Japan
    Expert Opin Pharmacother 6:2793-804. 2005
  7. ncbi request reprint Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Ann Oncol 16:430-6. 2005
  8. ncbi request reprint Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 18:317-23. 2007
  9. ncbi request reprint Chemoradiotherapy for lung cancer: current status and perspectives
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 9:435-43. 2004
  10. pmc Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
    K Goto
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Br J Cancer 91:659-65. 2004

Collaborators

Detail Information

Publications92

  1. ncbi request reprint A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 15:45-50. 2004
    ....
  2. ncbi request reprint Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients
    Y Ohe
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 31:100-6. 2001
    ....
  3. doi request reprint Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Clin Cancer Res 14:4206-12. 2008
    ..The objective of this study was to evaluate the efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B(12) in pretreated Japanese patients with advanced non-small cell lung cancer (NSCLC)...
  4. ncbi request reprint Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Panminerva Med 44:205-12. 2002
    ..At least 1-2% mortality should be expected for chemotherapy and thoracic radiotherapy. And in patients with poor PS, the expected mortality rate from chemotherapy is increased...
  5. ncbi request reprint Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, National Cancer Center Research Institute, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 94:729-34. 2003
    ..The present retrospective analysis showed that approximately 12% of patients with unresectable locally advanced NSCLC could be cured by various chemoradiotherapy regimens...
  6. ncbi request reprint Chemoradiotherapy for lung cancer
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo 104 0045, Japan
    Expert Opin Pharmacother 6:2793-804. 2005
    ..The incorporation of new agents, including target-based drugs, is one of the most promising strategies for improving the survival of patients...
  7. ncbi request reprint Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Ann Oncol 16:430-6. 2005
    ..The aims of this trial were to determine the maximum-tolerated doses (MTD) of combination therapy with amrubicin and cisplatin, and to assess the efficacy and safety at their recommended doses (RD)...
  8. ncbi request reprint Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 18:317-23. 2007
    ..To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design...
  9. ncbi request reprint Chemoradiotherapy for lung cancer: current status and perspectives
    Yuichiro Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 9:435-43. 2004
    ..The Japan Clinical Oncology Group is conducting clinical trials to develop new treatment strategies for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer...
  10. pmc Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
    K Goto
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Br J Cancer 91:659-65. 2004
    ..Nonhaematological toxicities were mild and transient in all patients. In conclusion, the PEI regimen is considered to be highly active and well tolerated for the treatment of sensitive relapsed SCLC...
  11. ncbi request reprint A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Lung Cancer 33:259-65. 2001
    ..The MTD of IFX was 1.5 g/m(2) administered for 3 days in this triplet combination. The clinical activity does not seem to justify the toxicity profile...
  12. ncbi request reprint A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer
    Y Akiyama
    Division of Thoracic Oncology, Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 31:482-7. 2001
    ..6%). CONCLUSION: We conclude that paclitaxel at 225 mg/m(2) in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer...
  13. pmc Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    M Ando
    The Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 76:1494-9. 1997
    ..We conclude that these schedules of sequential CPT-11 and VP-16 administration were inappropriate because of severe toxicities...
  14. pmc Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
    I Sekine
    Divisions of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 90:1125-8. 2004
    ....
  15. ncbi request reprint Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen
    S Niho
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6 5 1, Kashiwa, Chiba, Japan
    Lung Cancer 27:159-67. 2000
    ..The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately...
  16. pmc Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
    I Sekine
    Internal Medicine and Thoracic Oncology Division, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo, Japan
    Br J Cancer 88:808-13. 2003
    ..The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and 10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage IV SCLC and NSCLC...
  17. ncbi request reprint Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer
    T Kurata
    Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 31:93-9. 2001
    ..This is a well-tolerated and active regimen for non-small cell lung cancer. In view of the promising survival outcome, further evaluation in prospective randomized trials versus other regimens is warranted...
  18. ncbi request reprint Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity
    I Sekine
    Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 30:401-5. 2000
    ....
  19. ncbi request reprint Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer
    K Hotta
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Thorac Cardiovasc Surg 51:283-7. 2003
    ..The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence...
  20. ncbi request reprint Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
    Y Ohe
    Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, 6 5 1 Kashiwanoha, Kashiwa City, 277 8577, Chiba, Japan
    Eur J Cancer 37:54-63. 2001
    ..20-90.2, P=0.033) were also associated with treatment-related death from thoracic radiotherapy. The administration of mitomycin C in addition to cisplatin-based regimens for patients with lung cancer should be carefully considered...
  21. ncbi request reprint A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer
    K Hotta
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 31:596-600. 2001
    ..The combination of cisplatin and vinorelbine repeated every 3 weeks is well tolerated and has shown promising anti-tumor activity against non-small cell lung cancer...
  22. ncbi request reprint Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer
    Y Hosomi
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 29:546-9. 1999
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose of the three drugs in combination for such patients...
  23. ncbi request reprint In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines
    Y Sugimoto
    Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Chemother Pharmacol 30:417-22. 1992
    ..These in vitro data corresponded well to the results of clinical trials. Therefore, the colony-forming assay may be useful for the identification of the sensitivity of tumors according to phenotype...
  24. ncbi request reprint In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Cancer Res 49:4098-102. 1989
    ..However, K562/ADM was 2.4-fold more sensitive to CDDP than its parental cell line, K562 (P less than 0.001). These results suggested that the mechanism of CDDP resistance is different from that of multidrug resistance...
  25. ncbi request reprint Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer
    Hirokazu Watanabe
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 33:626-30. 2003
    ..We conducted a dose-finding and feasibility study in which we administered a fixed dose 3-h infusion of paclitaxel and an escalating dose of cisplatin in Japanese patients with advanced non-small cell lung cancer...
  26. ncbi request reprint Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
    S Niho
    Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Ann Oncol 23:2253-8. 2012
    ..We conducted a feasibility study of induction chemotherapy followed by gefitinib and thoracic radiotherapy (TRT) for unresectable locally advanced adenocarcinoma of the lung...
  27. ncbi request reprint Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect
    M Sakurai
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Oncology 47:251-6. 1990
    ..More extensive study of poly(A)poly(U) might give more fruitful results, which will give valuable information for future clinical trials of this lowly toxic promising agent...
  28. doi request reprint Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel
    Harukaze Yamamoto
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Oncology 75:169-74. 2008
    ..It was the aim of this study to investigate gender differences in the outcomes of carboplatin and paclitaxel chemotherapy in patients with unresectable stage IIIB-IV non-small cell lung cancer (NSCLC)...
  29. ncbi request reprint Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib
    Toshimi Takano
    Division of Internal Medicine, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Clin Cancer Res 13:5385-90. 2007
    ....
  30. ncbi request reprint Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer
    Hitoshi Kusaba
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 32:43-7. 2002
    ..This study was performed to determine the maximum tolerated dose of gemcitabine combined with cisplatin in a 3-week cycle regimen and to observe safety and efficacy for Japanese patients with advanced non-small cell lung cancer...
  31. doi request reprint Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients
    Yasushi Goto
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Thorac Oncol 3:412-6. 2008
    ..To identify factors, particularly the previous use of paclitaxel, that might influence the efficacy of subsequent docetaxel therapy...
  32. pmc Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line
    Y Sugimoto
    Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
    Br J Cancer 65:857-64. 1992
    ....
  33. ncbi request reprint Increased cytotoxic effects of photodynamic therapy in IL-6 gene transfected cells via enhanced apoptosis
    J Usuda
    Department of Surgery and Intractable Disease Research Center, Tokyo Medical University, Nishishinjuku, Tokyo, Japan
    Int J Cancer 93:475-80. 2001
    ..In conclusion, IL-6 expression plays a role in cellular sensitivity to PDT, and combination of IL-6 and PDT may provide a new strategy for cancer treatment...
  34. pmc Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials
    C Tanai
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 100:1037-42. 2009
    ..Trial designs and the doctor-patient relationship may have an impact on the patient accrual to randomised trials...
  35. ncbi request reprint Topoisomerase I targeting agents in small-cell lung cancer
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
    Curr Oncol Rep 3:170-8. 2001
    ..The Japan Clinical Oncology Group is intensively investigating other irinotecan-containing regimens and the incorporation of irinotecan into treatment of patients with limited-stage small-cell lung cancer...
  36. doi request reprint Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses
    Naoko Sanuki-Fujimoto
    Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
    Radiother Oncol 91:433-7. 2009
    ..We investigated the significance of treating clinically uninvolved lymph nodes by retrospectively analyzing the relationship between loco-regional failure and the irradiated volume...
  37. doi request reprint Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    Makoto Kawaishi
    Shien Lab, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 4:208-13. 2009
    ..Circulating endothelial cells (CECs) increase in cancer patients and play an important role in tumor neovascularization...
  38. pmc Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice
    Y Ohe
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 67:939-44. 1993
    ..This state may be responsible for the shortened survival of LLC-IL6 tumour-bearing mice...
  39. ncbi request reprint Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy
    Shigeo Yamazaki
    Division of Thoracic Oncology and Internal Medicine, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Lung Cancer 49:217-23. 2005
    ..The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear...
  40. ncbi request reprint Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung
    Yutaka Fujiwara
    Divisions of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 37:482-6. 2007
    ..The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear...
  41. doi request reprint EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan
    Toshimi Takano
    Division of Internal Medicine, Research Center for Cancer Prevention and Screening, National Cancer Center Hospital, Tokyo 104 0045, Japan
    J Clin Oncol 26:5589-95. 2008
    ..This study evaluated whether the presence of epidermal growth factor receptor (EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic marker in patients with advanced lung adenocarcinoma...
  42. doi request reprint A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer
    Chiharu Tanai
    National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 5:1068-74. 2010
    ..We conducted this phase I study to evaluate the safety, pharmacokinetics, and clinical activity of this combination in patients with previously treated advanced non-small cell lung cancer...
  43. ncbi request reprint Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung
    Tomoya Fukui
    Clinical Laboratory Division, National Cancer Center Hospital, 5 1 1 Tsukuji, Chuo Ku, Tokyo, Japan
    Cancer Sci 98:1714-9. 2007
    ..In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC...
  44. ncbi request reprint Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6
    Y Tatsumi
    Pharmacology Division, National Cancer Center Research Institute, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan
    Jpn J Cancer Res 92:768-77. 2001
    ..These results suggest a combined effect of AM-132 and cytokines on the blood supply to tumors...
  45. ncbi request reprint Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer
    Tomoya Fukui
    Division of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Clin Cancer Res 14:4751-7. 2008
    ..In this study, we verified the accuracy of EGFR mutation analysis in small samples by high-resolution melting analysis (HRMA), which is a rapid method using PCR amplification with a dye to analyze the melting curves in NSCLC...
  46. ncbi request reprint Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan
    Yutaka Fujiwara
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo, Japan
    Jpn J Clin Oncol 37:358-64. 2007
    ..To clarify the association between pre-treatment total bilirubin (PTB) level and severe toxicity in patients receiving cisplatin and irinotecan...
  47. ncbi request reprint Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis
    Kiyoaki Nomoto
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Clin Pathol 126:608-15. 2006
    ..The sensitivity of this analysis was 90% (19/21) and specificity, 100% (15/15). These results suggest that HRMA of archived cytologic specimens of advanced NSCLC is useful for detecting EGFR mutations in clinical practice...
  48. ncbi request reprint Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol
    Noboru Yamamoto
    Division of Internal Medicine, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    J Clin Oncol 23:1061-9. 2005
    ..This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing...
  49. ncbi request reprint Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older
    Toshio Shimizu
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:181-5. 2007
    ..The optimal treatment for limited-disease small cell lung cancer (LD-SCLC) in patients aged 75 years or older remains unknown...
  50. ncbi request reprint Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs
    I Sekine
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 13:1300-6. 2002
    ..Although the evaluation of new investigational drugs in phase I, II and III trials requires considerable time and patient resources, only a few of these drugs are ultimately established as anticancer drugs...
  51. ncbi request reprint Problems with registration-directed clinical trials for lung cancer in Japan
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospitalm Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Tohoku J Exp Med 213:17-23. 2007
    ..The development of infrastructure and human resources is an urgent task to ensure high-quality clinical trials without unnecessary delays...
  52. ncbi request reprint Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
    Ikuo Sekine
    Division of Thoracic Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 95:691-5. 2004
    ..4 months, and the 1-year, 2-year, and 3-year survival rates were 72%, 61%, and 50%, respectively. In conclusion, the recommended dose is the level 1 dose, and this regimen is feasible and promising in patients with stage III NSCLC...
  53. ncbi request reprint Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
    Kimie Sai
    Division of Biosignaling, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo, Japan
    Cancer Chemother Pharmacol 62:529-37. 2008
    ..In this study, the effects of CYP3A4 haplotypes including *16B on irinotecan PK/PD were investigated in irinotecan-administered patients...
  54. ncbi request reprint Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
    Toshimi Takano
    Division of Thoracic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Lung Cancer 45:93-104. 2004
    ..The risk-benefit ratio must be carefully considered...
  55. ncbi request reprint Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer
    Seiji Niho
    Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 34:69-73. 2004
    ..Therefore, febrile neutropenic inpatients are empirically treated with intravenous broad-spectrum antibiotics. Recently, several studies have suggested the presence of low-risk groups among febrile neutropenic patients...
  56. ncbi request reprint [Recent progress in the treatment of ED small cell lung cancer]
    Hiroshi Nokihara
    Department of Internal Medicine, National Cancer Center Hospital
    Nihon Rinsho 60:480-4. 2002
  57. ncbi request reprint Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Lung Cancer 65:219-22. 2009
    ..Male sex and poor performance status may be additional risk factors for the development of SREs in these patients...
  58. ncbi request reprint Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer
    Seiji Niho
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Lung Cancer 35:209-14. 2002
    ..A randomized phase III trial is warranted to compare this 3 consecutive weeks protocol with administration of docetaxel and cisplatin every third week...
  59. ncbi request reprint Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 4:518-21. 2009
    ..Whether chemotherapy would be equally effective in non-small cell lung cancer patients with stage IV disease (group A) and postoperative recurrence (group B) remains unclear...
  60. doi request reprint A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer
    Noboru Yamamoto
    Division of Internal Medicine, National Cancer Center Hospital, 5 1 1, Tsukiji Chuo ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 65:79-88. 2009
    ..Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients...
  61. ncbi request reprint Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 39:707-12. 2009
    ..To identify any gender differences in the outcomes of concurrent platinum-based chemotherapy and thoracic radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC)...
  62. ncbi request reprint Severe interstitial lung disease associated with amrubicin treatment
    Kiyotaka Yoh
    Division of Thoracic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, Japan
    J Thorac Oncol 5:1435-8. 2010
    ..We investigated the incidence of acute interstitial lung disease (ILD) in SCLC patients who had been treated with amrubicin...
  63. ncbi request reprint Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 98:1408-12. 2007
    ..1 kg and the total furosemide dose were significantly associated with group category. In conclusion, BW loss and total furosemide dose were associated with cisplatin nephrotoxicity...
  64. ncbi request reprint Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    Toshimi Takano
    Division of Internal Medicine, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    J Clin Oncol 23:6829-37. 2005
    ..To evaluate epidermal growth factor receptor (EGFR) mutations and copy number as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC) receiving gefitinib...
  65. ncbi request reprint Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients
    Yasuhito Fujisaka
    Division of Internal Medicine, National Cancer Center Hospital, 5 1 1, Tsukiji Chuo ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 36:477-82. 2006
    ..To assess the pharmacokinetic profile and time-course of trough concentrations and hemoglobin levels associated with subcutaneous weekly administration of epoetin beta in lung cancer patients with chemotherapy-induced anemia...
  66. ncbi request reprint A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC)
    Satoshi Ishikura
    Division of Radiation Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwa noha, Kashiwa 277 8577, Japan
    Int J Radiat Oncol Biol Phys 61:1117-22. 2005
    ..The purpose was to assess the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HART) after induction chemotherapy for Stage III non-small-cell lung cancer...
  67. ncbi request reprint Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:175-80. 2007
    ..The standard treatment of unresectable stage III non-small cell lung cancer is concurrent chemoradiotherapy in patients in good general condition, but where the optimal chemotherapeutic regimen has not been determined...
  68. ncbi request reprint Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials
    Ikuo Sekine
    Internal Medicine and Thoracic Oncology Division, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Treat Rev 30:359-68. 2004
    ..Although the evidence levels based on clinical trials available today are low, these results are helpful for clinical practice and future clinical trials for elderly patients with SCLC...
  69. ncbi request reprint Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Radiother Oncol 80:93-7. 2006
    ..To disclose characteristics of lung cancer patients developing radiation-induced lung injury treated with or without corticosteroid therapy...
  70. ncbi request reprint Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer
    Ikuo Sekine
    Division of Thoracic Oncology and Internal Medicine, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Lung Cancer 53:157-64. 2006
    ..However, extrapolation of clinical data obtained in one country to another population and global clinical trials were considered possible with adequate dose adjustment based on dose finding studies using a carefully projected protocol...
  71. doi request reprint Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
    Kazuhiko Yamada
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 101:188-95. 2010
    ..PF-3512676 as monotherapy and in combination with chemotherapy had an acceptable safety profile in Japanese patients with treatment-naive NSCLC...
  72. ncbi request reprint Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer
    Yukiko Nakajima
    National Institute of Health Sciences, Tokyo Women s Medical University, National Cancer Center Hospital, Japan
    Clin Pharmacol Ther 80:179-91. 2006
    ..We investigated the association between CYP3A4 haplotypes and pharmacokinetic parameters of paclitaxel metabolism...
  73. ncbi request reprint Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma
    Tetsuya Okano
    Proteome Bioinformatics Project, National Cancer Center Research Institute, Department of Surgery, Tokyo Medical University, and Clinical Laboratory Division, National Cancer Center Hospital, Japan
    Clin Cancer Res 13:799-805. 2007
    ..We aimed to identify candidate proteins for tumor markers to predict the response to gefitinib treatment...
  74. ncbi request reprint Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer
    Kouya Shiraishi
    National Cancer Center Research Institute, Tokyo, Japan
    J Clin Oncol 28:4945-52. 2010
    ..To identify polymorphisms in DNA repair genes that affect responses to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer (NSCLC)...
  75. ncbi request reprint CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
    Yoshiro Saito
    Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Tokyo, Japan
    Pharmacogenet Genomics 17:461-71. 2007
    ..Although large interindividual differences in CYP2C8 enzymatic activity and several nonsynonymous variations were reported, neither haplotype structures nor their associations with pharmacokinetic parameters of paclitaxel were reported...
  76. doi request reprint Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes
    Takashi Kohno
    Biology Division, National Cancer Center Research Institute, Tokyo 104 0045, Japan
    Carcinogenesis 31:834-41. 2010
    ..76 (95% CI = 2.53-9.47, P = 4.2 x 10(-7)). The present results indicated that individuals susceptible to lung ADC can be defined by combined genotypes of HLA-DQA1 and TERT...
  77. ncbi request reprint Differences in the quality of information on the internet about lung cancer between the United States and Japan
    Yasushi Goto
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Thorac Oncol 4:829-33. 2009
    ..Quality of information available over the Internet has been a cause for concern. Our goal was to evaluate the quality of information available on lung cancer in the United States and Japan and assess the differences between the two...
  78. ncbi request reprint Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:456-61. 2007
    ..469, 0.000 (not detected), 0.037, and 0.133, respectively. These data would provide fundamental and useful information for pharmacogenetic studies on OATP1B1-transported drugs in Japanese...
  79. ncbi request reprint Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population
    Maho Ukaji
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:462-7. 2007
    ..430, 0.636, and 0.318 allele frequencies, respectively. Another SNP, -26930A>G, with reduced VDR transcription was found at a 0.028 frequency. These findings would be useful for association studies on VDR variations in Japanese...
  80. ncbi request reprint Silefrin, a sodefrin-like pheromone in the abdominal gland of the sword-tailed newt, Cynops ensicauda
    K Yamamoto
    Department of Biology, School of Education, Waseda University, Nishiwaseda 1 6 1, Shinjuku ku, Tokyo, Japan
    FEBS Lett 472:267-70. 2000
    ..Both native and synthetic silefrin exerted an equipotent activity in attracting conspecific females...
  81. ncbi request reprint Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo
    H Fukumoto
    Pharmacology Division, National Cancer Center Research Institute, Tokyo
    Jpn J Cancer Res 88:501-5. 1997
    ..Systemic rIL-12 showed an anti-tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL-12 in vivo...
  82. ncbi request reprint Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population
    Naoko Tatewaki
    National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 24:118-26. 2009
    ..Three and six common haplotypes (N> or =10) in GSTT1 and GSTM1, respectively, accounted for most (>95%) inferred haplotypes. This information would be useful in pharmacogenomic studies of xenobiotics including anticancer drugs...
  83. ncbi request reprint Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population
    Hiroyuki Hichiya
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Setagaya Ku, Tokyo, Japan
    Drug Metab Dispos 33:630-6. 2005
    ..These results indicate that the novel CYP2C8 SNPs, 556C>T (R186X) and 556C>G (R186G), could influence the metabolism of CYP2C8 substrates such as paclitaxel and cerivastatin...
  84. ncbi request reprint Erlotinib in lung cancer
    Toshimi Takano
    N Engl J Med 353:1739-41; author reply 1739-41. 2005
  85. doi request reprint Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Sci 99:303-8. 2008
    ....
  86. doi request reprint A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer
    Katsuyuki Kiura
    Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 3:386-93. 2008
    ..Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan...
  87. ncbi request reprint Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients
    Hirokazu Watanabe
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo and Department of Radiology, Kobe University Graduate School
    Cancer Sci 94:1015-20. 2003
    ..0%). In conclusion, RECIST guidelines are adequate for evaluating tumor response to chemotherapy in terms of both validity in relation to tumor volume and inter-criteria reproducibility with the WHO criteria...
  88. ncbi request reprint Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo
    Tsugitaka Natsume
    Medicinal Research Department, Teikoku Hormone Mfg Co, Ltd, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Cancer Sci 94:826-33. 2003
    ..These findings strongly suggest that TZT-1027 has a potent anti-vascular effect, in addition to direct cytotoxicity...
  89. ncbi request reprint Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study
    Yasuo Morishima
    Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 36:655-61. 2006
    ..To determine a recommended dose of once-weekly epoetin-beta administration for anemic cancer patients receiving myelosuppressive chemotherapy, we conducted a multicenter, randomized, double-blind trial...
  90. ncbi request reprint Functional analysis of four naturally occurring variants of human constitutive androstane receptor
    Shinobu Ikeda
    Project term for Pharmacogenetics, National Institute of Health Sciences, 1 18 1, Kamiyoga, Setagaya Ku, Tokyo 158 8501, Japan
    Mol Genet Metab 86:314-9. 2005
    ..These data suggest that the His246Arg and Leu308Pro variants, especially His246Arg, may influence the expression of drug-metabolizing enzymes and transporters that are transactivated by CAR...
  91. ncbi request reprint Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice
    Ri Cui
    Department of Respiratory Medicine, Juntendo University, School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Lung Cancer 57:302-10. 2007
    ..Targeting the interaction between OPN and alphavbeta3 integrin could be effective for future development of anti-angiogenic therapeutic agents for patients with lung cancer...
  92. ncbi request reprint Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo
    Tsugitaka Natsume
    Pharmacological Research Department, Teikoku Hormone Mfg, Co Ltd, Kawasaki shi, Kanagawa, Japan
    Cancer Chemother Pharmacol 49:35-47. 2002
    ....